Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIIa Clinical Study Evaluating PEGylated Loxenatide Injection PEX168 in Monotherapy of Type 2 Diabetes Mellitus

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegloxenatide (Primary)
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Sponsors Jiangsu Hansoh Pharmaceutical

Most Recent Events

26 Aug 2024 New source identified and integrated (China Drug Trials: CTR20140233).
21 Jan 2017 Planned End Date changed from 1 Mar 2016 to 1 Feb 2017.
25 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com